KR20220103707A - Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 - Google Patents

Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 Download PDF

Info

Publication number
KR20220103707A
KR20220103707A KR1020227014562A KR20227014562A KR20220103707A KR 20220103707 A KR20220103707 A KR 20220103707A KR 1020227014562 A KR1020227014562 A KR 1020227014562A KR 20227014562 A KR20227014562 A KR 20227014562A KR 20220103707 A KR20220103707 A KR 20220103707A
Authority
KR
South Korea
Prior art keywords
gaba
disorder
receptor
compound
less
Prior art date
Application number
KR1020227014562A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 디. 레빈
닐 버클리
Original Assignee
엘리엄 테라퓨틱스 (유케이) 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘리엄 테라퓨틱스 (유케이) 엘티디 filed Critical 엘리엄 테라퓨틱스 (유케이) 엘티디
Publication of KR20220103707A publication Critical patent/KR20220103707A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020227014562A 2019-09-30 2020-09-23 Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 KR20220103707A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907763P 2019-09-30 2019-09-30
US62/907,763 2019-09-30
PCT/US2020/052167 WO2021067089A1 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20220103707A true KR20220103707A (ko) 2022-07-22

Family

ID=75338529

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227014562A KR20220103707A (ko) 2019-09-30 2020-09-23 Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법

Country Status (9)

Country Link
EP (1) EP4135710A4 (zh)
JP (1) JP2022552788A (zh)
KR (1) KR20220103707A (zh)
CN (1) CN115087450A (zh)
BR (1) BR112022006085A2 (zh)
CA (1) CA3159087A1 (zh)
IL (1) IL291835A (zh)
MX (1) MX2022003823A (zh)
WO (1) WO2021067089A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252314A1 (en) * 2020-06-08 2021-12-16 Eliem Therapeutics, Inc. Methods of treating female health conditions related to sex hormones
WO2024020953A1 (zh) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
HUE041369T2 (hu) * 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
NZ769008A (en) * 2014-10-16 2024-03-22 Sage Therapeutics Inc Compositions and methods for treating cns disorders
AU2017342521A1 (en) * 2016-10-14 2019-04-18 Marinus Pharmaceuticals, Inc Method of administering a neurosteroid to effect electroencephalographic (EEG) burst suppression
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof

Also Published As

Publication number Publication date
MX2022003823A (es) 2022-08-17
EP4135710A4 (en) 2023-12-06
EP4135710A1 (en) 2023-02-22
WO2021067089A1 (en) 2021-04-08
BR112022006085A2 (pt) 2023-03-14
CA3159087A1 (en) 2021-04-08
IL291835A (en) 2022-06-01
JP2022552788A (ja) 2022-12-20
CN115087450A (zh) 2022-09-20

Similar Documents

Publication Publication Date Title
EP3873883B1 (en) Method of synthesis
US11571432B2 (en) Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
EP2260022B1 (de) Substituierte cyclohexyldiamine
BR112020020008A2 (pt) Sais mono ácido de 6-aminoisoquinolinas e seus usos
KR20220103707A (ko) Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법
KR20200110648A (ko) 비라세믹 혼합물 및 이의 용도
BR122014023207A2 (pt) Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos
AU2019282231A1 (en) EAAT2 activators and methods of using thereof
CA2905570A1 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
JP6831376B2 (ja) トリアゾール誘導体
US11958821B2 (en) Phenethylamine compounds salts, polymorphic forms and methods of use thereof
BR112015000012B1 (pt) Composto e uso do composto
CN115515682A (zh) 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
US20240238313A1 (en) Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders
US20220296613A1 (en) Food-independent dosing of cv-10155 to treat gabaa disorders
CA3232914A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
WO2023130117A1 (en) Deuterated organic compounds and uses thereof
EP4199723A1 (en) Methods of treating fibromyalgia with neuroactive steroids
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
WO2023130119A1 (en) Deuterated organic compounds and uses thereof
TW202116760A (zh) 四員環類衍生物調節劑、其製備方法和應用
US20220048939A1 (en) Aromatic ring compound
JP2014532708A (ja) ニコチン性受容体非競合的モジュレーター

Legal Events

Date Code Title Description
A201 Request for examination